Skip to main content

In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo.

Publication ,  Journal Article
Kelsey, MD; Newby, LK
Published in: Ann Intern Med
July 2023

Nissen SE, Lincoff MA, Brennan D, et al; CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353-1364. 36876740.

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

July 2023

Volume

176

Issue

7

Start / End Page

JC75

Location

United States

Related Subject Headings

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Fatty Acids
  • Dicarboxylic Acids
  • Cardiovascular Diseases
  • Adult
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kelsey, M. D., & Newby, L. K. (2023). In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo. Ann Intern Med, 176(7), JC75. https://doi.org/10.7326/J23-0044
Kelsey, Michelle D., and L Kristin Newby. “In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo.Ann Intern Med 176, no. 7 (July 2023): JC75. https://doi.org/10.7326/J23-0044.
Kelsey, Michelle D., and L. Kristin Newby. “In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo.Ann Intern Med, vol. 176, no. 7, July 2023, p. JC75. Pubmed, doi:10.7326/J23-0044.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

July 2023

Volume

176

Issue

7

Start / End Page

JC75

Location

United States

Related Subject Headings

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Fatty Acids
  • Dicarboxylic Acids
  • Cardiovascular Diseases
  • Adult
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences